



Market Announcement

3 November 2023

Race Oncology Limited (ASX: RAC) – Trading Halt

Description

The securities of Race Oncology Limited ('RAC') will be placed in trading halt at the request of RAC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 7 November 2023 or when the announcement is released to the market.

Issued by

Lisa Banh

Senior Adviser, Listings Compliance

3 November 2023

Ms Lisa Bahn
Adviser Listings, ASX Compliance (Sydney)
Australian Securities Exchange Limited
20 Bridge Street
SYDNEY NSW 2000

By email: tradinghaltssydney@asx.com.au

Request for Trading Halt


Race Oncology Limited (ASX: RAC) (**Race**) requests an immediate trading halt be granted in respect of its shares on Friday, 3 November 2023.

The trading halt is requested to allow analysis and interpretation of data received relating to an investigator-initiated Phase 2 human clinical trial, where Race's lead asset, bisantrene, is being studied in patients with Acute Myeloid Leukaemia.

In accordance with ASX Listing Rule 17.1, Race provides the following information:

- (a) the trading halt is necessary for Race to analyse and interpret data and make an announcement in relation to an investigator-initiated Phase 2 human clinical trial;
- (b) the trading halt should remain in place until the earlier of the Company making an announcement in relation to the above matter or the commencement of trading on Tuesday, 7 November 2023;
- (c) Race is not aware of any reason why the trading halt should not be granted; and
- (d) Race is not aware of any other information necessary to inform the market about the trading halt.

Yours sincerely



Peter Webse
Company Secretary

Authorised for the release by the Board.